Kadcyla is medicine for the adjuvant treatment of people with HER2-positive early breast cancer with the residual invasive disease after neoadjuvant treatment. Roche stock price rose for more than 21% over the past 12 months…
Kadcyla is medicine for the adjuvant treatment of people with HER2-positive early breast cancer with the residual invasive disease after neoadjuvant treatment. Roche stock price rose for more than 21% over the past 12 months…